| Compound | Teriparatide |
|---|---|
| Category | Approved anabolic bone agent |
| Class | Other Injectables |
| Evidence tier | Approved medicine |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers Teriparatide, a approved anabolic bone agent, graded "Approved medicine" in this catalog's evidence system. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
The 1-34 fragment of parathyroid hormone, approved (Forteo) as daily injection for osteoporosis in patients at high fracture risk.
Mechanism of Action
Intermittent teriparatide favors bone formation over resorption — the reverse of continuous PTH exposure — rebuilding trabecular architecture.
Research and Evidence
The pivotal fracture-prevention trial (n=1,637) showed substantial vertebral and non-vertebral fracture reduction.
Safety and Side Effects
Labeled cautions include hypercalcemia monitoring and a historical rodent osteosarcoma signal that restricted duration of use.
Frequently Asked Questions
What is the evidence tier of Teriparatide?
Teriparatide is graded "Approved medicine" on this site. This compound exists as an approved medicine in at least one major jurisdiction. Approval applies to specific, labeled indications and to the regulated product — not to compounded or research-grade copies.
Is Teriparatide an approved medicine?
Teriparatide exists as an approved medicine in at least one major jurisdiction — but approval covers the regulated product and its labeled indications only. Compounded or research-grade versions of the same molecule are not the approved product.
Where can I read the primary studies for Teriparatide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- DailyMed — teriparatide prescribing information. [source]
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.